Alphatec Holdings, Inc.

Alphatec Holdings, Inc.

ATECNYSE / NASDAQHealthcareSmall cap

$6.68-$0.22 (-3.2%)

Last close · Data as of Nov 20, 2026

Market cap
$1.2B
Revenue
$764.2M
Net margin
-18.8%
ROCE
-16.9%

-65.9% over the last year

Alphatec Holdings, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-38.5%
3M
-28.1%
6M
-18.9%
1Y
-65.9%
5Y
-40.7%

52-week range

Day change -$0.22 (-3.2%) from $7 to $7 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in ATEC, bought on each weekday since 2021.

News & filings

What Alphatec Holdings filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 143 million US dollars in fiscal 2025.

Strengths (1)

  • Current assets are 2.06 times current liabilities.
  • Shareholders' equity is small against the company's size, so return on equity and debt to equity are not shown.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. The company manufactures and sells implants, instruments, imaging equipment, and spare parts.

Read moreShow less

Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. The company manufactures and sells implants, instruments, imaging equipment, and spare parts. It offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; SafeOp Neural InformatiX System that automates electromyographic, somatosensory evoked potential, and motor evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems. It also provides split-blade retractors; Sigma-ALIF Access System, a procedure-specific access system; spinal implants and fixation systems comprising NanoTec and Invictus, as well as various standalone implants for height restoration and stabilization. In addition, the company provides biologics comprising 3D ProFuse Osteoconductive Bioscaffold; AlphaGRAFT Demineralized Bone Matrix (DBM) comprising demineralized human tissue; BioCORE Moldable Bioactive Graft, a synthetic mineral-collagen composite matrix that can be molded to fit the bone defect; AlphaGRAFT DBM Fibers comprising demineralized fibers; AlphaGRAFT Cellular Bone Matrix (CBM), a growth factor-enriched cellular bone matrix; AlphaGRAFT CBM that is delivered in granular, fiber, or structural form; and Amnioshield Amniotic Tissue Barrier, an allograft for spinal surgical barrier applications. The company sells its products through a network of independent sales agents and direct sales representatives. The company was founded in 1990 and is headquartered in Carlsbad, California.

Sector
Healthcare
Shares outstanding
148.4M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$1.2B
P/B
98.1x
EV / Sales
2.2x
P/S
1.6x
52-week high
$22.68
52-week low
$6.68

Profitability

Operating margin
-7.6%
Net margin
-18.8%
EBITDA margin
-2.0%
ROE
-1154.3%
ROCE
-16.9%
ROIC
-17.2%
ROA
-18.1%
Asset turnover
0.97

Growth

Revenue
$764.2M
Revenue growth, 1Y
25.0%
Revenue CAGR, 3Y
29.6%
Net profit growth, 1Y
-11.6%
Free cash flow
-$4.4M

Solvency

Current ratio
2.06
Debt / Equity
47.99
Debt / Assets
0.75
CFO / Net profit
-0.32
Cash / Market cap
13.2%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$764.2M
Cost of revenue$232.3M
Gross profit$531.9M
Operating expenses$589.9M
Research and development$76.3M
Selling, general and administrative$498.5M
Operating income-$58.0M
Interest and other-$85.4M
Pretax income-$143.4M
Tax and other-$40.0k
Net income-$143.4M

Revenue and net profit

Revenue grew 25.0% in FY2025; net profit is the dashed line.

Alphatec Holdings, Inc. revenue and net profit by fiscal year
Alphatec Holdings, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$350.9M-$151.3M
FY2023$482.3M-$186.6M
FY2024$611.6M-$162.1M
FY2025$764.2M-$143.4M

Cash flows

FY2025: $45.2M from operations, -$4.4M free after investment (dashed).

Alphatec Holdings, Inc. operating and free cash flow by fiscal year
Alphatec Holdings, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$75.1M-$133.4M
FY2023-$78.5M-$165.5M
FY2024-$44.7M-$137.8M
FY2025$45.2M-$4.4M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$764.2M+25.0%1Y
EBITDA
-$14.9M
Net profit
-$143.4M
Cash from operations
$45.2M
Free cash flow
-$4.4M
Revenue CAGR, 3Y
29.6%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$764.2M-$14.9M-$143.4M-$4.4M-1153.8%+25.0%-11.6%

Monthly returns

Month-by-month returns of ATEC across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$791.2M
Liabilities$778.8M
Equity$12.4M
Paid-in capital$1.5B
Retained earnings-$1.4B
Treasury stock$25.1M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; ATEC highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

EV / Sales, for the companies without earnings

  1. Alphatec Holdings, Inc. (this company)2.2x

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Alphatec Holdings, Inc.ATECthis company$1.2B—98.1x-1154.3%—
Ardent Health, Inc.ARDT$1.2B9.1x1.0x10.5%5.7x
Inspire Medical Systems, Inc.INSP$1.2B8.4x1.6x18.6%14.3x
IRADIMED CORPORATIONIRMD$1.2B53.2x12.6x23.8%41.9x
CareDx, Inc.CDNA$1.2B-55.9x3.9x-7.0%-248.1x
Kestra Medical Technologies, Ltd.KMTS$1.2B-10.5x5.8x-55.4%-10.2x
AMN Healthcare Services, Inc.AMN$1.2B—1.8x-14.9%19.3x
Schrödinger, Inc.SDGR$1.2B-11.5x3.3x-28.4%-6.6x
Wave Life Sciences Ltd.WVE$1.2B—2.3x-39.4%—
Peer median—-1.1x2.8x-11.0%5.7x

Year-to-date ROI

ATEC since 1 January, against earlier years.

Historical volatility

ATEC's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Alphatec Holdings, Inc. operating margin by fiscal year
Alphatec Holdings, Inc. operating margin by fiscal year
DateOperating margin
FY2022-34.5%
FY2023-30.7%
FY2024-20.1%
FY2025-7.6%
LineFY2025
Cost of revenueCost Of Revenue$232.3M
Gross profitGross Profit$531.9M
Operating expensesOperating Expense$589.9M
Research and developmentResearch And Development$76.3M
Selling, general and administrativeSelling General And Administration$498.5M
Depreciation and amortisationDepreciation And Amortization In Income Statement$15.1M
Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement$15.1M
Amortization$15.1M
Amortisation of intangiblesAmortization Of Intangibles Income Statement$15.1M
Total expensesTotal Expenses$822.1M
Pretax incomePretax Income-$143.4M

Learn while you research

Academy chapters picked for Alphatec Holdings, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Growth Investing25% revenue growth is in the top tier, learn how to value growth.7 min read
  3. 03 Leverage RatiosDebt/Equity of 47.99 is elevated, understand what that means for solvency.6 min read
  4. 04 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  5. 05 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  6. 06 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
Browse the full Equiscale Academy →